Cow Milk Protein allergy

Cow’s milk protein allergy (CMPA) is the most common food allergy in infancy and early childhood, with a variable clinical presentation ranging from mild gastrointestinal symptoms to life-threatening anaphylaxis. The increasing awareness and recognition of food allergies worldwide, along with the significant impact of CMPA on infant growth, family life, and health systems, highlight the need for standardized, evidence-based diagnostic and management protocols.

This Clinical Practice Guideline (CPG) provides adapted, evidence-informed recommendations for the diagnosis and management of CMPA in children, tailored to the Egyptian healthcare context. It draws upon internationally recognized guidelines, specifically the BSACI 2014 and DRACMA 2010 guidelines, and integrates them with local clinical expertise to ensure feasibility, effectiveness, and cultural appropriateness.

The guideline aims to support physicians, especially pediatricians, family doctors, and primary care providers, in making accurate diagnostic decisions and optimizing treatment pathways for children suspected to have CMPA. Ultimately, the goal is to improve patient outcomes, reduce diagnostic errors, and enhance resource utilization across the national healthcare system. 

This guideline focuses on prevention and management of CMPA
. Is intended for use by all healthcare professionals involved in the care of infants and children with cow’s milk protein allergy (CMPA), including pediatricians, general practitioners, allergists, dietitians, and other allied healthcare professionals.
It covers the diagnosis, management, and follow-up of IgE-mediated and non-IgE mediated CMPA in different healthcare settings, aiming to standardize care, improve outcomes, and ensure evidence-based practice.

Cow’s milk allergy may be defined as a reproducible adverse reaction of an immunological nature induced by cow’s milk protein.                                                                    Strong

CMA can be classified into immediate onset and delayed onset according to timing of symptoms and organ involvement                                                                         Strong

Symptoms of immediate onset hypersensitivity present within minutes to less than 2hours                                                           Strong

IgE mediated symptoms affect several target organs, Skin (urticaria,, angioedema),Respiratory (rhinitis/rhino conjunctivitis/asthma/ wheeze, angioedema / stridor), GIT (oral allergy syndrome, vomiting, pain, flatulence and diarrhea) and or CVS ( anaphylactic shock)                                                                                     Strong

Delayed hypersensitivity symptoms to CMP appear more than 2 hours (usually several hours) up to 8 days.                                                                                                Strong

Non-IgE mediated disease varies widely in clinical presentation from eczema exacerbations to life-threatening shock from gastrointestinal fluid loss secondary to inflammation [Food Protein Induced Enterocolitis Syndrome (FPIES)]

- Gastrointestinal symptoms of non-IgE mediated CMA are variable and affect the entire gastrointestinal tract. CMA should be considered in these circumstances where symptoms fail to respond to standard therapy or where other features of allergy are present.  Strong

Lactose intolerance can be confused with non-IgE mediated cow’s milk allergy as symptoms overlap. Lactose intolerance should be considered where patients present only with typical gastrointestinal symptoms                                                Strong

A skin prick test (SPT) weal size ≥ 5 mm or ≥ 2 mm in younger infants) is strongly predictive of CMPA.

Negative skin test results are useful for confirming the absence of IgE-mediated reactions, with negative predictive values exceeding 95%                                                                                                               Conditional

In settings where oral food challenge is not a requirement (no expertise or not well prepared), the clinical diagnosis of IgE mediated disease is made by a combination of typically presenting symptoms, e.g. urticaria and/or angio-oedema with vomiting and/or wheeze, soon after ingestion of cow’s milk, and evidence of sensitization (presence of specific IgE).                                                                                            Conditional

In patients with low pretest probability of IgE-mediated CMA we suggest using milk-specific IgE measurement with a cut-off value of ‡0.35 IU/L as a triage test to avoid oral food challenge     Strong                                                                                Conditional

The use of milk elimination is an integral step toward the diagnosis of  CMA

Conditional

The treatment following the diagnosis of cow’s milk allergy is complete avoidance of cow’s milk and foods containing cow’s milk.                                                          Conditional 

Diagnostic dietary elimination should be maintained for at least 6 weeks            Conditional

In settings where an oral food challenge is a requirement (routinely done) in all patients suspected of IgE mediated CMA, we recommend using oral food challenge with cow’s milk as the only test without measuring a cow’s milk-specific IgE level as a triage or an add-on test to establish a diagnosis.                                                                            Strong 

In practice, OFC  is rarely required to make the diagnosis of CMPA . A food challenge may be necessary to confirm the diagnosis in IgE-mediated disease where there is conflict between the history and diagnostic tests.

Food elimination and reintroduction is recommended for the assessment of non-IgE mediated cow’s milk allergy where there is diagnostic uncertainty.            Conditional

OFC is not indicated in initial diagnosis of CMPA if:

1- History of anaphylaxis

2-  History of Severe delayed reaction (Food Protein Induced Enterocolitis)

3-  Generalized immediate allergic reaction with positive specific IgE                                                              Conditional

Reintroduction can be performed at home or may need to be supervised in hospital.                               Conditional

In breast-fed infants breast milk (with elimination of CM from the mother’s diet) is suitable for most infants with cow’s milk allergy.

In children after 2 years of age, a substitute formula may not be necessary.

In infants and children less than 2 years of age, replacement with a substitute formula is mandatory.

The different types of formulas used in CMPA are:

1.  Amino acid formula (AAF)

2.  Extensively hydrolyzed formula of cow's milk proteins (eHF).

3.   Soy formula (SF) more than 6 months of age                                                             Conditional

In children with IgE-mediated CMPA at high risk of anaphylactic reactions, we suggest amino acid formula rather than extensively hydrolyzed milk formula.                                                                                                  Conditional

In children with IgE-mediated CMPA at low risk of anaphylactic reactions, we suggest extensively hydrolyzed milk formula over amino acid formula.                                                                                                         Conditional 

In children with IgE-mediated CMA, we suggest extensively hydrolyzed milk formula rather than soy formula.

Conditional

Individuals should be reassessed at 6-12 monthly intervals from 12 months of age to assess for suitability of reintroduction.                                                                strong

The reintroduction is achieved by a graded exposure according to the milk ladder with the less allergenic baked milk.                                                                                                                                                             Conditional

Reintroduction can be performed at home or may need to be supervised in hospital.                                Conditional

  

➡️Guideline development process and methods

After reviewing all the inclusion and exclusion criteria and quality appraisal results, the GDG/ GAG recommended using the following source original clinical practice guidelines (CPGs):

1- Diagnosis and Rationale for Action against Cow’s Milk Allergy (DRACMA) Guidelines (2014).

2- Milk allergy guideline developed by WAO  (2023).

We conducted Adolopment for these guidelines: (Adoption, Adaptation, and Development)

         -    Adoption for most of the guideline recommendations.

         -   Adaptation for 2 recommendations according to GRADE criteria to be suitable to our Economic implications (Evidence-to-Decision (EtD) table was done)

         -    Development of Good Practice Statements

Recommendations and Good Practice Statements (GPS)

This version of the CPG includes recommendations and good practice statements on the following three sub-sections:

A.Diagnosis of Cow’s Milk Allergy (CMA) The guideline covers the age groups from birth to 2 years. This guideline emphasizes the importance of early and accurate diagnosis of CMA, including clinical suspicion, history taking, and diagnostic tests (such as elimination diets, skin prick tests, specific IgE, and oral food challenges.

B. This section includes recommendations and good practice statements on nutritional management, formula selection, breastfeeding support, pharmacological treatment (if needed), monitoring growth and development, and duration of dietary elimination.

C. This section includes recommendations and good practice statements on Prevention of  CMPA   through exclusive breastfeeding for the first 6 months of life, and the potential benefit of early introduction of allergenic foods after 4 months of age to reduce the risk of CMA.

We can summarize the guidelines’ recommendations for CMPA in the following:

• Appropriate diagnostic tools for diagnosis of CMPA.
• Nutritional management.
• Indications for use of different infant formulas.
• Role of breastfeeding and maternal diet.
• Prevention strategies.

➡️Guideline Registration

PREPARE (Practice guideline REgistration for transPAREncy), WHO Collaborating Center for Guideline Implementation and Knowledge Translation, EBM Center, University of Lanzhou, Lanzhou, China. Registration Number: ((submitted and in process)). Link: http://www.guidelines-registry.org/